WuXi to build manufacturing facility in U.S.

By The Science Advisory Board staff writers

May 19, 2020 -- WuXi Biologics announced it has signed a deal with Worcester Business Development to build a clinical and commercial manufacturing facility in Worcester, MA.

The 107,000-sq-ft facility is expected to be completed in 2022. The location is the first U.S. biomanufacturing facility for WuXi. According to the company, the campus will be located on a 46-acre plot and will create 150 new jobs for the local economy.

WuXi is a Hong-Kong based drug discovery and clinical and commercial manufacturing organization. It currently has over 100 projects in phase I and II clinical development and 16 in phase III development, as well as one project in commercial manufacturing.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.